ArticleAsiaIntervention2025
Performance of drug-coated balloons in East Asian and Caucasian patients: a post hoc analysis of the EASTBOURNE Registry.
Article in AsiaIntervention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- When Follow-Up Shapes the Outcome: Lessons From a Drug-Coated Balloon in East Asian Practice.JACC. Asia · 2026Article
- What do we need to maximise the effect of drug-coated balloons? An Asian perspective.AsiaIntervention · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment of coronary artery disease (CAD) has evolved significantly over the years with the emergence of drug-coated balloons (DCBs). Research has shown that ethnicity can influence procedural approaches and clinical outcomes. Despite this, there are still limited data on DCB performance in different ethnic groups - particularly Caucasian and East Asian patients. Aims: In this Methods: EASTBOURNE was a prospective, investigator-driven, multicentre, international study investigating the safety and efficacy of a sirolimus-coated balloon (SCB). A propensity-matching analysis was performed to mitigate differences in variables. The primary endpoint was target lesion revascularisation (TLR) at 12 months. Results: From September 2016 to December 2020, EASTBOURNE enrolled 2,123 patients from 38 centres. This analysis includes 2,084 patients: 1,657 in the Caucasian group and 427 in the East Asian group. After propensity matching, we analysed 602 patients with no significant differences in clinical characteristics. In procedural terms, the Caucasian population had higher baseline percentage diameter stenosis and contrast media usage, but they had lower predilatation rates and used shorter SCBs at higher pressures; the rate of bailout stenting was also higher. Twelve-month follow-up showed higher rates of TLR (6.0% vs 1.5%; p<0.001), whereas major adverse cardiovascular events, all-cause death, and spontaneous myocardial infarction did not differ significantly. Bleeding Academic Research Consortium Type 2-5 bleedings were lower (0.0 vs 5.0%; p<0.001). Conclusions: In this subgroup analysis of the EASTBOURNE Registry comparing patients of Caucasian versus East Asian origin treated with SCBs, there were higher incidences of TLR but less bleeding in the Caucasian population compared to East Asian patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.